The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia

Abstract

Preeclampsia is associated with thrombosis of the intervillous or spiral artery. A deletion/insertion polymorphism (4G or 5G) in the promoter of the plasminogen activator inhibitor type 1 (PAI-1) gene is suggested to be involved in regulating the synthesis of the inhibitor, 4G allele, being associated with the enhanced gene expression and plasma PAI-1 levels. We assessed the association between preeclampsia and the 4G/5G polymorphism of the PAI-1 gene in 115 preeclamptic patients, 210 pregnant controls, and 298 healthy volunteer controls. The frequency of the homozygotes for the 4G allele was significantly higher in the patients than in the control pregnant women (P ϭ 0.04) or in the healthy volunteers (P ϭ 0.02). The 4G allele frequency was also significantly higher in the patients than in the control group of pregnant women (P ϭ 0.03) and in the healthy volunteers (P ϭ 0.02). These results suggest that the presence of the 4G/4G genotype of the PAI-1 gene is one of the risk factors for preeclampsia.

Correlation between factor VII and PAI-1 genetic variants and recurrent miscarriage

“…The -675 4G allele determines increased PAI-1 concentration and enhanced prothrombotic activity. The -675 4G/5G polymorphism has been suggested to be involved in the etiology of intrauterine fetal death, intrauterine growth restriction, preterm placental abruption, recurrent miscarriage, and preeclampsia [20,21].…”

Implication of an AGT Haplotype in a Multigene Association Study With Pregnancy Hypertension

“…10 Other chromosomal regions that have showed suggestive linkage include 4, 11 2q23, 8 11q23-24, 10 7q36, 12 12q, 3p, 15q, 10q, and 22q. 13 In parallel, association studies have suggested the involvement of candidate genes in susceptibility to preeclampsia, mostly related to oxidative stress, vasoactive substances, and coagulation disorders: lipoprotein lipase (LPL), 14 5-10 methylenetetrahydrofolate reductase (MTHFR), 15 glutathione-S transferase pi (GSTP1), 16 factor V (F5), 15,17 apolipoprotein E (APOE), 18 plasminogen activator inhibitor-1 (SERPINE1), 19 microsomal epoxide hydrolase 1 (EPHX1), 20 endothelial nitric oxide synthase (NOS3), 21 angiotensinogen (AGT), 22 and tumor necrosis factor-␣ (TNF). 23 Essential hypertension is an elusive disease.…”

Analysis haemostatic system gene polymorphism in pregnant women without complications from Russia and Ukraine

“…Можно предполагать, что удельный вклад данного полиморфиз-ма в возникновении осложнений беременности в разных популяциях может значительно варьировать. Действи-тельно, для большинства европейских стран, как и для Японии, были выявлены положительные ассоциации между полиморфизмом в гене Pai1 и риском возникно-вения акушерских осложнений (Fabbro et al, 2003;Hakli et al, 2003;Wiwanitkit, 2006, Yamada et al, 2000. По всей вероятности данный полиморфизм можно отнести к самостоятельным факторам риска осложнений беремен-ности.…”